Concepedia

S.K. Kho

SK

Statistics

Publications

3

Citations

157

H-Index

3

Active since

1997

Affiliations

Queen Elizabeth Hospital(Current)

National Cancer Centre Singapore

University of Ulsan

Merck & Co., Inc., Rahway, NJ, USA (United States)

St. Luke's Medical Center

S.K. Kho is an author at Queen Elizabeth Hospital specializing in medicine, oncology, and cancer pharmacology.

Publications per year

1997–2022

3

Publications

3

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

Anthony T.�C. Chan, V.H.F. Lee, R-L. Hong et al. · Annals of Oncology · 2022 · 107 citations · Full text

, , +17

858O Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)

Anthony T.�C. Chan, Victor Lee, R-L. Hong et al. · Annals of Oncology · 2021 · 37 citations · Full text

, , +14

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer

Andr x E Planting, S.K. Kho, M. van der Burg et al. · Cancer Chemotherapy and Pharmacology · 1997 · 13 citations · Full text

, , +14

1–3 of 3